Copyright Reports & Markets. All rights reserved.

Global Combination Vaccine and Multivalent Vaccine Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Combination Vaccine and Multivalent Vaccine by Type
    • 1.3.1 Overview: Global Combination Vaccine and Multivalent Vaccine Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Combination Vaccine and Multivalent Vaccine Consumption Value Market Share by Type in 2025
    • 1.3.3 Combination Vaccine
    • 1.3.4 Multivalent Vaccine
  • 1.4 Global Combination Vaccine and Multivalent Vaccine Market by Application
    • 1.4.1 Overview: Global Combination Vaccine and Multivalent Vaccine Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Centers for Disease Control and Prevention
    • 1.4.4 Others
  • 1.5 Global Combination Vaccine and Multivalent Vaccine Market Size & Forecast
  • 1.6 Global Combination Vaccine and Multivalent Vaccine Market Size and Forecast by Region
    • 1.6.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Combination Vaccine and Multivalent Vaccine Market Size by Region, (2021-2032)
    • 1.6.3 North America Combination Vaccine and Multivalent Vaccine Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Combination Vaccine and Multivalent Vaccine Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size and Prospect (2021-2032)
    • 1.6.6 South America Combination Vaccine and Multivalent Vaccine Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Merck & Co.
    • 2.1.1 Merck & Co. Details
    • 2.1.2 Merck & Co. Major Business
    • 2.1.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.1.4 Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Merck & Co. Recent Developments and Future Plans
  • 2.2 Pfizer
    • 2.2.1 Pfizer Details
    • 2.2.2 Pfizer Major Business
    • 2.2.3 Pfizer Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.2.4 Pfizer Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer Recent Developments and Future Plans
  • 2.3 Sanofi Pasteur
    • 2.3.1 Sanofi Pasteur Details
    • 2.3.2 Sanofi Pasteur Major Business
    • 2.3.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.3.4 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sanofi Pasteur Recent Developments and Future Plans
  • 2.4 GlaxoSmithKline
    • 2.4.1 GlaxoSmithKline Details
    • 2.4.2 GlaxoSmithKline Major Business
    • 2.4.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.4.4 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GlaxoSmithKline Recent Developments and Future Plans
  • 2.5 BioNTech
    • 2.5.1 BioNTech Details
    • 2.5.2 BioNTech Major Business
    • 2.5.3 BioNTech Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.5.4 BioNTech Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 BioNTech Recent Developments and Future Plans
  • 2.6 Moderna
    • 2.6.1 Moderna Details
    • 2.6.2 Moderna Major Business
    • 2.6.3 Moderna Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.6.4 Moderna Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Moderna Recent Developments and Future Plans
  • 2.7 Dynavax
    • 2.7.1 Dynavax Details
    • 2.7.2 Dynavax Major Business
    • 2.7.3 Dynavax Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.7.4 Dynavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Dynavax Recent Developments and Future Plans
  • 2.8 Novavax
    • 2.8.1 Novavax Details
    • 2.8.2 Novavax Major Business
    • 2.8.3 Novavax Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.8.4 Novavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novavax Recent Developments and Future Plans
  • 2.9 Sino Biopharm
    • 2.9.1 Sino Biopharm Details
    • 2.9.2 Sino Biopharm Major Business
    • 2.9.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.9.4 Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sino Biopharm Recent Developments and Future Plans
  • 2.10 Kangtai Bio
    • 2.10.1 Kangtai Bio Details
    • 2.10.2 Kangtai Bio Major Business
    • 2.10.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.10.4 Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Kangtai Bio Recent Developments and Future Plans
  • 2.11 Zhifei Biological
    • 2.11.1 Zhifei Biological Details
    • 2.11.2 Zhifei Biological Major Business
    • 2.11.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.11.4 Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Zhifei Biological Recent Developments and Future Plans
  • 2.12 Walvax
    • 2.12.1 Walvax Details
    • 2.12.2 Walvax Major Business
    • 2.12.3 Walvax Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.12.4 Walvax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Walvax Recent Developments and Future Plans
  • 2.13 Minhai Biological
    • 2.13.1 Minhai Biological Details
    • 2.13.2 Minhai Biological Major Business
    • 2.13.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.13.4 Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Minhai Biological Recent Developments and Future Plans
  • 2.14 Sinovac
    • 2.14.1 Sinovac Details
    • 2.14.2 Sinovac Major Business
    • 2.14.3 Sinovac Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.14.4 Sinovac Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Sinovac Recent Developments and Future Plans
  • 2.15 Wantai Biological
    • 2.15.1 Wantai Biological Details
    • 2.15.2 Wantai Biological Major Business
    • 2.15.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.15.4 Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Wantai Biological Recent Developments and Future Plans
  • 2.16 Wanbangde Pharmaceutical
    • 2.16.1 Wanbangde Pharmaceutical Details
    • 2.16.2 Wanbangde Pharmaceutical Major Business
    • 2.16.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.16.4 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Wanbangde Pharmaceutical Recent Developments and Future Plans
  • 2.17 AIM Bio
    • 2.17.1 AIM Bio Details
    • 2.17.2 AIM Bio Major Business
    • 2.17.3 AIM Bio Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.17.4 AIM Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 AIM Bio Recent Developments and Future Plans
  • 2.18 Antejin Biotechnology
    • 2.18.1 Antejin Biotechnology Details
    • 2.18.2 Antejin Biotechnology Major Business
    • 2.18.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.18.4 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Antejin Biotechnology Recent Developments and Future Plans
  • 2.19 Lanzhou Institute of Biological Products
    • 2.19.1 Lanzhou Institute of Biological Products Details
    • 2.19.2 Lanzhou Institute of Biological Products Major Business
    • 2.19.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.19.4 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Lanzhou Institute of Biological Products Recent Developments and Future Plans
  • 2.20 Wuhan Institute of Biological Products
    • 2.20.1 Wuhan Institute of Biological Products Details
    • 2.20.2 Wuhan Institute of Biological Products Major Business
    • 2.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.20.4 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Wuhan Institute of Biological Products Recent Developments and Future Plans
  • 2.21 Beijing Institute of Biological Products
    • 2.21.1 Beijing Institute of Biological Products Details
    • 2.21.2 Beijing Institute of Biological Products Major Business
    • 2.21.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.21.4 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.21.5 Beijing Institute of Biological Products Recent Developments and Future Plans
  • 2.22 Chengdu Institute of Biological Products
    • 2.22.1 Chengdu Institute of Biological Products Details
    • 2.22.2 Chengdu Institute of Biological Products Major Business
    • 2.22.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product and Solutions
    • 2.22.4 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.22.5 Chengdu Institute of Biological Products Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Combination Vaccine and Multivalent Vaccine Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Combination Vaccine and Multivalent Vaccine by Company Revenue
    • 3.2.2 Top 3 Combination Vaccine and Multivalent Vaccine Players Market Share in 2025
    • 3.2.3 Top 6 Combination Vaccine and Multivalent Vaccine Players Market Share in 2025
  • 3.3 Combination Vaccine and Multivalent Vaccine Market: Overall Company Footprint Analysis
    • 3.3.1 Combination Vaccine and Multivalent Vaccine Market: Region Footprint
    • 3.3.2 Combination Vaccine and Multivalent Vaccine Market: Company Product Type Footprint
    • 3.3.3 Combination Vaccine and Multivalent Vaccine Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Combination Vaccine and Multivalent Vaccine Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Combination Vaccine and Multivalent Vaccine Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Combination Vaccine and Multivalent Vaccine Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Combination Vaccine and Multivalent Vaccine Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Combination Vaccine and Multivalent Vaccine Consumption Value by Type (2021-2032)
  • 6.2 North America Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2032)
  • 6.3 North America Combination Vaccine and Multivalent Vaccine Market Size by Country
    • 6.3.1 North America Combination Vaccine and Multivalent Vaccine Consumption Value by Country (2021-2032)
    • 6.3.2 United States Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Combination Vaccine and Multivalent Vaccine Consumption Value by Type (2021-2032)
  • 7.2 Europe Combination Vaccine and Multivalent Vaccine Consumption Value by Application (2021-2032)
  • 7.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country
    • 7.3.1 Europe Combination Vaccine and Multivalent Vaccine Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 7.3.3 France Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Combination Vaccine and Multivalent Vaccine Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Region
    • 8.3.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Consumption Value by Region (2021-2032)
    • 8.3.2 China Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 8.3.5 India Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Combination Vaccine and Multivalent Vaccine Consumption Value by Type (2021-2032)
  • 9.2 South America Combination Vaccine and Multivalent Vaccine Consumption Value by Application (2021-2032)
  • 9.3 South America Combination Vaccine and Multivalent Vaccine Market Size by Country
    • 9.3.1 South America Combination Vaccine and Multivalent Vaccine Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country
    • 10.3.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Combination Vaccine and Multivalent Vaccine Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Combination Vaccine and Multivalent Vaccine Market Drivers
  • 11.2 Combination Vaccine and Multivalent Vaccine Market Restraints
  • 11.3 Combination Vaccine and Multivalent Vaccine Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Combination Vaccine and Multivalent Vaccine Industry Chain
  • 12.2 Combination Vaccine and Multivalent Vaccine Upstream Analysis
  • 12.3 Combination Vaccine and Multivalent Vaccine Midstream Analysis
  • 12.4 Combination Vaccine and Multivalent Vaccine Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Combination Vaccine and Multivalent Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Combination Vaccine and Multivalent Vaccine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Combination Vaccine and Multivalent Vaccine market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Combination Vaccine and Multivalent Vaccine market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Combination Vaccine and Multivalent Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Combination Vaccine and Multivalent Vaccine market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Combination Vaccine and Multivalent Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Combination Vaccine and Multivalent Vaccine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., Pfizer, Sanofi Pasteur, GlaxoSmithKline, BioNTech, Moderna, Dynavax, Novavax, Sino Biopharm, Kangtai Bio, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Combination Vaccine and Multivalent Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Combination Vaccine
    Multivalent Vaccine
    Market segment by Application
    Hospital
    Centers for Disease Control and Prevention
    Others
    Market segment by players, this report covers
    Merck & Co.
    Pfizer
    Sanofi Pasteur
    GlaxoSmithKline
    BioNTech
    Moderna
    Dynavax
    Novavax
    Sino Biopharm
    Kangtai Bio
    Zhifei Biological
    Walvax
    Minhai Biological
    Sinovac
    Wantai Biological
    Wanbangde Pharmaceutical
    AIM Bio
    Antejin Biotechnology
    Lanzhou Institute of Biological Products
    Wuhan Institute of Biological Products
    Beijing Institute of Biological Products
    Chengdu Institute of Biological Products
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Combination Vaccine and Multivalent Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Combination Vaccine and Multivalent Vaccine, with revenue, gross margin, and global market share of Combination Vaccine and Multivalent Vaccine from 2021 to 2026.
    Chapter 3, the Combination Vaccine and Multivalent Vaccine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Combination Vaccine and Multivalent Vaccine market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Combination Vaccine and Multivalent Vaccine.
    Chapter 13, to describe Combination Vaccine and Multivalent Vaccine research findings and conclusion.

    Buy now